IL310813A - OFATUMUMAB for the treatment of multiple sclerosis in children - Google Patents
OFATUMUMAB for the treatment of multiple sclerosis in childrenInfo
- Publication number
- IL310813A IL310813A IL310813A IL31081324A IL310813A IL 310813 A IL310813 A IL 310813A IL 310813 A IL310813 A IL 310813A IL 31081324 A IL31081324 A IL 31081324A IL 310813 A IL310813 A IL 310813A
- Authority
- IL
- Israel
- Prior art keywords
- ofatumumab
- treating pediatric
- pediatric
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163233524P | 2021-08-16 | 2021-08-16 | |
| US202163254684P | 2021-10-12 | 2021-10-12 | |
| EP21206466 | 2021-11-04 | ||
| PCT/EP2022/071132 WO2023020802A1 (en) | 2021-08-16 | 2022-07-27 | Ofatumumab for treating pediatric ms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310813A true IL310813A (en) | 2024-04-01 |
Family
ID=82940064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310813A IL310813A (en) | 2021-08-16 | 2022-07-27 | OFATUMUMAB for the treatment of multiple sclerosis in children |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240343821A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4387999A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024531314A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240046200A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3229704A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL310813A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023020802A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4252847A3 (en) | 2016-08-15 | 2023-11-15 | Novartis AG | Regimens and methods of treating multiple sclerosis using ofatumumab |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| WO2021204994A1 (en) * | 2020-04-09 | 2021-10-14 | Novartis Ag | Ofatumumab for treating ms while maintaining serum igg |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
-
2022
- 2022-07-27 JP JP2024509123A patent/JP2024531314A/ja active Pending
- 2022-07-27 EP EP22755216.3A patent/EP4387999A1/en active Pending
- 2022-07-27 CA CA3229704A patent/CA3229704A1/en active Pending
- 2022-07-27 WO PCT/EP2022/071132 patent/WO2023020802A1/en not_active Ceased
- 2022-07-27 US US18/683,858 patent/US20240343821A1/en active Pending
- 2022-07-27 KR KR1020247007246A patent/KR20240046200A/ko active Pending
- 2022-07-27 IL IL310813A patent/IL310813A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4387999A1 (en) | 2024-06-26 |
| WO2023020802A1 (en) | 2023-02-23 |
| KR20240046200A (ko) | 2024-04-08 |
| US20240343821A1 (en) | 2024-10-17 |
| CA3229704A1 (en) | 2023-02-23 |
| JP2024531314A (ja) | 2024-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL312981A (en) | care | |
| GB202016058D0 (en) | Therapeautic treatment | |
| GB202013321D0 (en) | Treatment process | |
| GB202116743D0 (en) | Treatment | |
| GB202108224D0 (en) | Treatment | |
| GB202103122D0 (en) | Treatment | |
| GB202003722D0 (en) | Treatment | |
| GB202100311D0 (en) | Treatment for Lipodystrophy | |
| GB202018400D0 (en) | Treatment | |
| GB202002711D0 (en) | Treatment | |
| GB202318845D0 (en) | Treatment | |
| GB202311007D0 (en) | Treatment | |
| GB202304853D0 (en) | Treatment | |
| GB202218460D0 (en) | Treatment | |
| GB202214206D0 (en) | Treatment | |
| GB202212125D0 (en) | Treatment | |
| GB202204288D0 (en) | Treatment | |
| GB202204070D0 (en) | Treatment | |
| GB202201069D0 (en) | Treatment | |
| GB202114373D0 (en) | Treatment | |
| GB202109812D0 (en) | Treatment | |
| GB202109815D0 (en) | Treatment | |
| GB202104666D0 (en) | COVID-19 treatment | |
| GB202104416D0 (en) | Treatment reginmens | |
| GB202103957D0 (en) | Treatment |